

---

## Product Data Sheet

---

Product Name: SAR247799

Cat. No.: GC65910

### Chemical Properties

Cas. No. 1315311-14-8

Formula  $C_{21}H_{16}ClN_3O_5$

M.Wt 425.82

Solubility DMSO : 33.33 mg/mL (78.27 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased **sphingosine-1 phosphate receptor-1 (S1P1 )** agonist, with EC<sub>50</sub>s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome<sup>[1][2][3][4]</sup>.

SAR247799 (0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM; 10 min) induces a concentration-dependent phosphorylation of extracellular-regulated kinase-1/2 (Erk1/2) and protein kinase B (Akt) in HUVECs<sup>[1]</sup>.

SAR247799 (0-10 μM, 8 min) induces impedance change in HUVECs in a dose-dependent manner<sup>[1]</sup>.

SAR247799 (1 μM, 1st) does not cause desensitization demonstrated by Ca<sup>2+</sup> flux assay in S1P1-Chinese hamster ovary (CHO) cells<sup>[1]</sup>.

SAR247799 (1 and 3 mg/kg; p.o.; 1 h before renal occlusion) dose dependently reduces the severity of ischemia/reperfusion (I/R)-induced acute kidney injury<sup>[1]</sup>.

SAR247799 (0.3, 1, 3 mg/kg; i.v.) dose dependently increases the coronary conductance ratio in pig model of coronary endothelial dysfunction<sup>[1]</sup>.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**


---

SAR247799 (30-min intravenous administration; 8- to 10-week-old farm pig) exposure ( $C_{max}$  and AUC) increases with dose in pigs. Pharmacokinetic parameters [1]:

| Dose (mg/kg) | N | $C_{max}$ (g/mL) | $T_{max}$ (h)  | $T_{last}$ (h) | $AUC_{0-last}$ (g.h/mL) | Cl (L/h/kg) | Vss (L/kg) | $T_{1/2z}$ (h) |
|--------------|---|------------------|----------------|----------------|-------------------------|-------------|------------|----------------|
| 1            | 4 | 2.08 (8)         | 0.5 [0.5]      | [8-48]         | 11.8 (46)               | 0.113 (75)  | 0.516 (11) | 5.62 (57)      |
| 3            | 7 | 8.10 (12)        | 0.5 [0.5]      | [24-72]        | 42.2 (23)               | 0.0754 (30) | 0.446 (16) | 6.21 (28)      |
| 10           | 3 | 36.7 (5)         | 0.5 [0.5-0.75] | 72             | 294 (13)                | 0.0343 (13) | 0.338 (7)  | 7.73 (8)       |
| 30           | 6 | 112 (27)         | 0.5 [0.5-1.0]  | [48-72]        | 908 (16)                | 0.0338 (18) | 0.294 (11) | 7.35 (11)      |

Mean values with (CV%) except  $T_{max}$ , which is expressed as median value with [range] and  $T_{last}$  as [range].  $C_{max}$ , maximum concentration.  $T_{max}$ , time at which maximum concentration achieved.  $T_{last}$ , last time point sampled.  $AUC_{0-last}$ , area under curve from 0 to last time point. Cl, clearance. Vss, volume at steady state or volume of distribution.  $T_{1/2z}$ , elimination half-life. N, number of animals.

Animal Model: Acute kidney injury rats (12 to 15-week-old Fischer rats)[1]

Dosage: 1 and 3 mg/kg

Administration: P.o.; administered 1 hour before renal occlusion.

Result: Inhibited the increase in serum creatinine (89 and 96% at 1 and 3 mg/kg) and urea (61 and 85% at 1 and 3 mg/kg). Protected renal proximal tubules against necrosis and blunted the development of interstitial hemorrhage.

Animal Model: Acute kidney injury rats (8- to 12-week-old Fischer rats)[1]

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

---

## Product Data Sheet

---

Dosage: 3 mg/kg

Administration: P.o.; twice a day for 7 days and twice a day for 7 day

Result: Showed a dosedependent trend for reducing macrophage.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**